We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biomarkers Predict Progression to Adenocarcinoma

By LabMedica International staff writers
Posted on 20 Mar 2013
A series of micro ribonucleic acid (miRNA) expression signatures may help to define progression of the precancerous condition Barrett's esophagus into esophageal adenocarcinoma. More...


To reduce the mortality of esophageal adenocarcinoma, the best hope in the near term is to detect it at its early stage, or even better, to prevent the progression of esophageal adenocarcinoma from its premalignant lesion, which is called Barrett's esophagus.

Scientist at the M.D.Anderson Cancer Center (Houston, TX, USA) extracted RNA from total of 105 snap frozen tissues, including 35 normal, 34 Barrett’s esophagus, and 36 esophageal adenocarcinoma. They used the real-time PCR-based TaqMan Human Micro-RNA Card Set (Applied Biosystems; Carlsbad, CA, USA) that enables accurate quantitation of 754 human miRNAs. They compared hundreds of miRNAs in normal esophageal epithelia and in Barrett's esophagus and esophageal adenocarcinoma tissues of different histological grades with distinct progression risks.

The investigators identified a number of differentially expressed miRNAs at each histological stage. They also identified a small number of miRNAs that were significantly different between Barrett's esophagus and esophageal adenocarcinoma. Specifically, downregulation of the miRNA miR-375 and upregulation of five miRNAs of the miR-17-92 and homologue family seemed to differentiate Barrett's esophagus and esophageal adenocarcinoma.

The patients with Barrett's esophagus with low levels of miR-375 and/or high levels of the other five miRNAs that were found to be upregulated in esophageal adenocarcinoma, are at increased risk for malignant progression and should be under intensive surveillance, screening and treatment of their Barrett's esophagus.

Xifeng Wu, MD, the senior author of the study, said, "Defining the protein-coding genes targeted by the differentially expressed microRNAs we identified may provide significant biological insights into the development of esophageal adenocarcinoma. Moreover, these genes may themselves become promising biomarkers to predict Barrett's esophagus progression as well as potential preventive and therapeutic targets." The study was published on March 5, 2013, in the journal Cancer Prevention Research.

Related Links:
M. D. Anderson Cancer Center
Applied Biosystems



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.